HER2+乳腺癌患者癌组织中P53、SBEM的表达及其与临床病理特征、预后的关系  

Expression of P53 and SBEM in cancer tissues of HER2+breast cancer patients and their relationship with clinicopathological characteristics and prognosis

作　　者：郝辉 罗鹏 王炳胜 杨林 张素静 HAO Hui;LUO Peng;WANG Bingsheng;YANG Lin;ZHANG Sujing(Department of Oncology,Cangzhou People's Hospital,Cangzhou 061000,Hebei,China;The First Affiliated Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei,China)

机构地区：[1]沧州市人民医院肿瘤内科,河北沧州061000 [2]河北医科大学附属第一医院肿瘤二科,河北石家庄050000

出　　处：《贵州医科大学学报》2025年第2期306-312,共7页Journal of Guizhou Medical University

基　　金：河北省医学科学研究课题计划项目(20211395)。

摘　　要：目的探讨肿瘤蛋白53(tumor protein 53,P53)和乳腺上皮小黏蛋白(mucin of mammary gland epithelium,SBEM)在人表皮生长因子受体2阳性(human epidermal growth factor receptor 2,HER2+)乳腺癌患者癌组织中的表达,分析二者与患者临床病理特征及预后的关系。方法收集67例乳腺癌患者的一般临床资料[年龄、雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、增殖标志物(kdidel67,Ki67)、肿瘤大小、临床分期、组织学分级及有无淋巴结转移];取所有患者肿瘤组织,采用免疫组织化学(EnVision)法检测P53和SBEM蛋白的表达;采用电话、门诊及住院复查随访等方式对所有患者随访4~69个月,收集疾病复发及时间、生存状态并计算无病生存期(disease-free survival,DFS);采用Kaplan-Meier法绘制DFS曲线,采用Cox单因素和多因素分析乳腺癌患者预后的危险因素。结果HER2+乳腺癌患者癌组织中P53、SBEM阳性表达率分别为61.2%、32.8%,二者的表达呈正相关(r=0.296,P=0.015);P53、SBEM表达均与患者淋巴结转移、临床分期、组织学分级有关;P53表达阳性和阴性的中位DFS分别为49.158个月和51.836个月,SBEM表达阳性和阴性的中位DFS分别为46.219个月和49.855个月;P53(+)SBEM(+)组、P53(+)SBEM(-)组、P53(-)SBEM(+)组及P53(-)SBEM(-)组的DFS分别为45.526个月、48.347个月、49.552个月及51.540个月,其中P53(+)SBEM(+)组患者预后最差、P53(-)SBEM(-)组患者的预后最好(P<0.001);Cox多因素分析显示淋巴结转移、临床分期、P53阳性、SBEM表达阳性是乳腺癌预后的独立危险因素(P<0.05)。结论HER2+乳腺癌患者癌组织中P53和SBEM的表达上调,与淋巴结转移、临床分期、组织学分级等有关。Objective To investigate the expression of tumor protein 53(P53)and mammary epithelial mucin(SBEM)in cancer tissues of human epidermal growth factor receptor 2 positive(HER2+)breast cancer patients,and their relationship with clinicopathological characteristics and prognosis were analyzed.Methods The general clinical data of 67 breast cancer patients were collected[age,estrogen receptor(ER),progesterone receptor(PR),proliferation marker(Ki67),tumor size,clinical stage,histological grade,and presence or absence of lymph node metastasis],tumor tissues from all patients were collected and immunohistochemistry(EnVision)was used to detect the expression of P53 and SBEM proteins;all patients were followed up for 4 to 69 months by various methods such as telephone,outpatient and inpatient review follow-up,and data on disease recurrence and disease recurrence were collected.Time,survival the DFS curve,and Cox single factor and multifactor were used to analyze the prognostic risk factors of breast cancer patients.Results The positive expression rate of P53 in cancer tissues of HER2+breast cancer patients was 61.2%(41/67);the positive expression rate of SBEM was 32.8%(22/67).There was a positive correlation between the expression of P53 and SBEM(r=0.296,P=0.015).And the expressions of P53 and SBEM were related to lymph node metastasis,clinical stage and histological grade.The median DFS of positive and negative P53 expression were 49.158 months and 51.836 months respectively,and the median DFS of positive and negative SBEM expression were 46.219 months and 49.855 months respectively.P53(+)SBEM(+)group,The DFS of P53(+)SBEM(-)group,P53(-)SBEM(+)group and P53(-)SBEM(-)group were 45.526 months,48.347 months,49.552 months and 51.540 months respectively,among which P53(+)SBEM(+)group has the worst prognosis,and P53(-)SBEM(-)group has the best prognosis(P<0.001).Cox multivariate analysis showed that lymph node metastasis,clinical stage,positive expression of P53 and SBEM were independent risk factors for the prognosis of breast

关 键 词：乳腺肿瘤 肿瘤蛋白53 乳腺上皮黏蛋白 人表皮生长因子受体2阳性 预后 

分 类 号：R737[医药卫生—肿瘤]